论文部分内容阅读
德国柏林自由大学Ｂｒａｎｄｔ等进行的一项多中心研究显示 ,重症强直性脊柱炎 (ＡＳ)患者 ,接受抗肿瘤坏死因子α单克隆抗体Ｉｎｆｌｉｘｉｍａｂ治疗 ,病情可获得持续性改善。这是第—个用Ｉｎｆｌｉｘｉｍａｂ治疗ＡＳ随访 1年的报告。研究共纳入 11例符合纽约标准的活动性?
A multicenter study by Brandt et al. At the Free University of Berlin in Germany showed that patients with severe ankylosing spondylitis (AS) underwent treatment with Infliximab, a monoclonal antibody to tumor necrosis factor α, with sustained improvement in their condition. This is the first report of a 1-year follow-up of AS treated with Infliximab. Study included a total of 11 cases of activities in line with New York standards?